Development of advanced analgesic dressings for chronic wound healing by Boateng, Joshua et al.
Wafers seems to be a very promising system for delivery of analgesic drug to the wound. Further studies 
are in progress to evaluate in vitro activity of the dressings and role of HA in the wound healing process
 Catanzano O. et al. Carbohydrate Polymers (2015), in press; Kianfar F. et al. Colloids Surf B Biointerfaces. 2013 Mar 1;103:99-106; Boateng J.S. et al. Int J Pharm. 2010 Apr 15;389(1-2):24-31; Pawar H.V. et al. J Pharm Sci. 2014 Jun;103(6):1720-33.
WAFERS CHARACTERIZATION
Depth of 
compression
(mm)
CARR
Mean peak force 
(N) (±s.d.) 
Relaxation
distance (mm) 
(±s.d.) 
Compression
recovery ratio 
(±s.d.)
Compaction
(mm) (±s.d.)
0.2 0.38 (0.06) 0.16 (0.01) 0.81 (0.02) 0.02 (0.04)
0.5 0.62 (0.08) 0.45 (0,03) 1.13 (0.08) 0.05 (0.03)
1 1.58 (0.06) 0.81 (0.03) 1.24 (0.05) 0.19 (0.03)
2 2.50 (0.10) 1.37 (0.04) 1.47 (0.04) 0.63 (0.04)
3 6.65 (0.21) 1.83 (0.02) 1.64 (0.02) 1.17 (0.02)
Depth of 
compression
(mm)
CARR/HA50
Mean peak force 
(N) (±s.d.) 
Relaxation
distance (mm) 
(±s.d.) 
Compression
recovery ratio 
(±s.d.)
Compaction
(mm) (±s.d.)
0.2 1.04 (0.57) 0.18 (0.01) 1.13 (0.02) 0.02 (0.00)
0.5 2.27 (0.07) 0.35 (0,01) 1.43 (0.04) 0.15 (0.01)
1 4.22 (0.43) 0.62 (0.01) 1.63 (0.04) 0.38 (0.01)
2 5,92 (0.20) 1.04 (0.12) 1.95 (0.26) 0.96 (0.12)
3 8.61 (0.76) 1.49 (0.09) 2.03 (0.10) 1.51 (0.09)
Depth of 
compression
(mm)
CARR/HA30
Mean peak force 
(N) (±s.d.) 
Relaxation
distance (mm) 
(±s.d.) 
Compression
recovery ratio 
(±s.d.)
Compaction
(mm) (±s.d.)
0.2 0.61 (0.10) 0.18 (0.01) 1.16 (0.03) 0.02 (0.00)
0.5 1.57 (0.18) 0.37 (0.04) 1.40 (0.21) 0.13 (0.04)
1 3.49 (0.54) 0.54 (0.68) 1.47 (0.04) 0.32 (0.02)
2 4.47 (0.08) 1.12 (0.02) 1.74 (0.04) 0.88 (0.02)
3 5.54 (0.87) 2.12 (0.12) 1.43 (0.08) 0.88 (0.12)
Depth of 
compression
(mm)
CARR/HA10
Mean peak force 
(N) (±s.d.) 
Relaxation
distance (mm) 
(±s.d.) 
Compression
recovery ratio 
(±s.d.)
Compaction
(mm) (±s.d.)
0.2 0.43 (0.06) 0.20 (0.01) 1.01 (0.02) 0.02 (0.04)
0.5 1.04 (0.11) 0.37 (0.05) 1.39 (0.20) 0.13 (0.05)
1 2.16 (0.09) 0.71 (0.01) 1.42 (0.03) 0.29 (0.01)
2 3.68 (0.15) 1.25 (0.04) 1.61 (0.06) 0.75 (0.04)
3 4.81 (0.37) 1.68 (0.23) 1.87 (0.16) 1.32 (0.23)
• Critical parameters for handling properties
• HA causes an increase in resistance to compressive deformation 
• A compression recovery ratio further from one indicate a permanent deformation 
of the wafers with a possible modification of internal structure
Wafers of known weight were placed into beakers of test solution. The dressings were
removed from the solution at periodic intervals (0.5-48 hours) and gently blotted to
remove excess liquid from the outer surface. The hydrogels were then reweighed. The
water uptake of hydrogels was calculated by the following equation:
(%) = (W –W0)/W0*100, 
where W0 and W represent the weight of the hydrogels before and after the experiment
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The presence of HA within the wafers 
decreases water uptake
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• Increase in resistance to compressive deformation with 
increasing concentration of HA
• More rigid wafers in presence of HA
Wafers of known weight were placed on a wire mesh into a custom made release
chamber using Simulated Wound Fluid (SWF) as dissolution media. The dissolution
medium was constantly stirred throughout the experiment using a magnetic bar and the
temperature was maintained at 37°C. 1 ml aliquot of dissolution media were withdrawn
at predetermined time intervals and analyzed by HPLC. The same amount of new media
was added to maintain constant the volume during the experiment.
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• Controlled LID release over 6 hours
• Drug release driven by water uptake
DEVELOPMENT OF ADVANCED ANALGESIC 
DRESSINGS FOR CHRONIC WOUND HEALING
The aim of this work is to develop advanced multifunctional wound dressings for local delivery of an 
analgesic drug that can help to manage pain associated with chronic leg ulcers in older adults. Wafers with 
different compositions of carrageenan (CARR) Hyaluronan (HA), and lidocaine (LID) was proposed to 
obtain a system with analgesic properties and able to promote the wound healing process. 
MATERIALS WAFERS PREPARATION
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Primary drying
Freezing
Secondary drying
 Linear sulphated polysaccharides extracted 
from red edible seaweeds
 Widely used in the food industry for their 
gelling, thickening, and stabilizing properties
 Used in pharmaceutics as inactive excipient 
in pills/tablets
 GRAS substance
 Rapid onset of action and intermediate 
duration of efficacy
 Widely employed to relieve itching, burning, 
and pain from skin inflammations, injected as 
a dental anaesthetic, 
 Already used as local anaesthetic in wound 
healing
 Principal component of the human connective 
tissues
 Direct action on tissue repair processes, 
including wound healing
 Already used in industrial production of 
advanced dressing
Carrageenan Hyaluronic Acid
HYASIS® (Novozymes)
Freeze dryingMixing 40°C
CARR/HA composite wafers
• Wafers with different shapes and sizes can be  prepared by freeze drying
• CARR/HA wafers can be easily loaded with LID
• LID does not influence formulation process and final wafers
Sample* CARR (% w/w) HA (% w/w) LID Loading (%) 
CARR 100 - 10
CARR/HA50 50 50 10
CARR/HA30 70 30 10
CARR/HA10 90 10 10
*All gel formulations are at 2% w/v
CARR/HA50
CARR/HA10
CARR
CARR/HA70
Porosity
(%)
Density 
(mg/cm3)
Water
absorption (%)
Water 
Retention (%)
EWC (%)
CARR 82.25 ± 4.53 36.78 ± 1.51 3782.7 ± 86.9 67.3 ± 1.8 97,40 ± 0.09
CARR/HA50 85,00 ± 2.62 30.32 ± 1.25 3640.2 ± 39,1 78.8 ± 4.1 97.33 ± 0.03
CARR/HA30 87.95 ± 3.55 29.69 ± 1.75 3394.1 ± 112.5 77.1 ± 2.4 97.04 ± 0.21
CARR/HA10 89.06 ± 2.98 30.55 ± 0.60 3270,7 ± 70.8 76.3 ± 1.1 97.03 ± 0.08
